Sanofi: FDA lifts clinical hold on fitusiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following R&D Meeting
December 18, 2017 9:20 AM ESTBofA/Merrill Lynch reiterates a Neutral rating and $49.00 price target on Sanofi (NYSE: SNY) following the company's R&D Q&A session.
Although Sanofi suggested its PIII lung program for cemiplimab has PFS as a primary endpoint, it clarified today that the... More
